<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147728</url>
  </required_header>
  <id_info>
    <org_study_id>Rvision-001</org_study_id>
    <nct_id>NCT04147728</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLC</brief_title>
  <acronym>Rvision-001</acronym>
  <official_title>Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in Non-small Cell Lung Cancer：An Exploratory Single-Arm Phase II Clinical Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether stereotactic radiosurgery combination with
      Anlotinib is safe, effective in the treatment of limited brain metastases with Perilesional
      edema in non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether stereotactic radiosurgery combination with
      Anlotinib is safe, effective in the treatment of limited brain metastases with perilesional
      edema in non-small cell lung cancer. The sample size is 50. Patients start to take Anlotinib
      1 week before the MRI-based simulation，12mg/d QD，day1~14, day22~36.Edema index will be used
      to evaluate the effectiveness of Anlotinib. The &quot;Edema index (EI)&quot; is calculated per the
      equation of &quot;edema index= (peri-tumoral edema volume+ tumor volume)/tumor volume.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EI</measure>
    <time_frame>1 month</time_frame>
    <description>Edema Index. The &quot;Edema index (EI)&quot; is calculated per the equation of &quot;edema index= (peri-tumoral edema volume+ tumor volume)/tumor volume.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>1 year</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>3 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>3 months</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iORR</measure>
    <time_frame>3 months</time_frame>
    <description>intracranial objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iPFS</measure>
    <time_frame>3 months</time_frame>
    <description>intracranial progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRS rate</measure>
    <time_frame>1 month</time_frame>
    <description>the rate of SRS after anlotinib treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Stereotactic Body Radiation Therapy</condition>
  <arm_group>
    <arm_group_label>SRS Combination With Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic Radiosurgery Combination With Anlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.</description>
    <arm_group_label>SRS Combination With Anlotinib</arm_group_label>
    <other_name>Antiangiogenic agents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <description>Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases</description>
    <arm_group_label>SRS Combination With Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients voluntarily participate in this study, signed informed consent.

          2. Patients pathologically diagnosed as non-small cell lung cancer, with brain metastases
             and measurable lesions;

          3. Patients aged between 18 -80 years; with expected survival time&gt;3 months.

          4. Patients with no more than 5 brain metastases

          5. Patients with normal organ function within 7 days prior to treatment, the following
             criteria are met:

             a) blood routine examination criteria : i) hemoglobin (HB) ≥90g/L; ii) absolute
             neutrophil count (ANC) ≥1.5×10e9/L; iii) platelet (PLT) ≥80×10e9/L; b) biochemical
             tests meet the following criteria: i) total bilirubin (TBIL) ≤1.5 times of upper limit
             of normal (ULN); ii) alanine aminotransferase (ALT) and aspartate aminotransferase
             (AST) ≤2.5 ULN, if liver metastasis occurred, ALT and AST ≤5 ULN; iii) serum
             creatinine (Cr) ≤1.5 ULN or creatinine clearance (CCr) ≥60mL/min;

          6. Female patients should agree to use contraceptives during and within 6 months after
             the study.

        Exclusion Criteria:

          1. Patients who had previously used antiangiogenic agents within 1 month;

          2. Patients with small cell lung cancer (including small cell carcinoma and non-small
             cell carcinoma mixed lung cancer);

          3. Patient with lung squamous cell carcinoma that involved pulmonary hilar, or non-small
             cell lung cancer with hemoptysis;

          4. Patients with cerebral infarction and cerebral hemorrhage;

          5. Patients without perilesional edema；

          6. Patients with more than grade 2 (NCI-CTCAE v4.0) acute toxicity reaction due to any
             previous treatment.

          7. Patients with factors that affect oral medication (such as cannot swallow, chronic
             diarrhea and intestinal obstruction, etc.);

          8. Patients with visceral dissemination or severe symptoms, which could cause death in
             short term;

          9. Patients with any other severe and/or uncontrolled disease;

         10. Patients who received a surgery, a biopsy or a significant traumatic injury within 1
             month;

         11. Patients with any signs or medical history of bleeding, unhealed wounds, ulcers or
             fractures, regardless of the severity;

         12. Patients underwent artery or venous thrombotic events within 2 months, such as deep
             vein thrombosis and pulmonary embolism;

         13. Patients with a history of psychotropic medicine abuse and cannot quit or have mental
             disorders;

         14. Patients with disease which will severely endanger their security and could not
             complete this study, according to the judgement of researchers；

         15. Patients who still can't tolerate SRS after anlotinib treatment, even after adding
             mannitol, and have to receive steroid treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongqing Zhuang, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongqing Zhuang, doctor</last_name>
    <phone>13051776232</phone>
    <email>hongqingzhuang@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuxia Wang, doctor</last_name>
    <phone>15001292991</phone>
    <email>lily31415926@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist.</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongqing Zhuang, Doctor</last_name>
      <phone>13051776232</phone>
      <email>hongqingzhuang@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yuxia Wang, Doctor</last_name>
      <phone>15001292991</phone>
      <email>lily31415926@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Enmin Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongchun Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xin Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yun Guan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

